Bill Would Cap Cannabis Concentrates Potency at 30% in Washington

在华盛顿,法案将大麻浓缩物的效力限制在30%

2021-02-13 05:21:47 Ganjapreneur

本文共662个字,阅读需2分钟

For the second year in a row, a bill has emerged in Washington state aimed at limiting the potency of cannabis concentrate products. The bill, HB 1463, has bi-partisan sponsors and is scheduled for a hearing on February 12 in the Washington House. The legislation cites health concerns around “high potency” cannabis and includes a recent consensus statement from a group of Washington State University and University of Washington cannabis researchers. “Use of cannabis with high THC concentration increases the chances of developing cannabis use disorder or addiction to cannabis, particularly among adolescents. High-potency cannabis use can have lifelong mental health consequences, which often manifest in adolescence or early adulthood. Daily cannabis use, particularly of high-potency products, increases the risk of developing a psychotic disorder, like schizophrenia, and is related to an earlier onset of symptoms compared to people who do not use cannabis.” — Consensus statement excerpt If passed, the bill would limit cannabis concentrates to 30 percent THC and raise the age of purchase to 25. An exemption would be made for registered medical cannabis patients. Bo Jackson, a Washington cannabis consumer who lobbied last year against a similar bill, said he is organizing to push back on this year’s attempt. “This will incentivize black market sales, as cannabis concentrates of more than 30% are popular and sought by consumers,” he told Ganjapreneur. “The age restriction, 25 for concentrates, is inconsistent with current regulations we see on tobacco and alcohol and seems to be targeting cannabis consumers. While every industry is subject to regulation, those regulations need to benefit the entire community. This bill creates an arbitrary restriction that hurts consumers, industry, and medical users.” End Authored By: Lukas is a freelance writer and medical cannabis activist who lives in Tacoma. When he’s not writing about cannabis or working to bring a better medical cannabis system to Washington, he likes to DJ, play adaptive sports and volunteer in his Tacoma community. He supports national legalization and the opening up of the medical cannabis market in all 50 states.
华盛顿州连续第二年出现一项法案,旨在限制大麻浓缩产品的效力。这项名为HB1463的法案由两党共同发起,定于2月12日在华盛顿众议院举行听证会。该立法引用了“高效力”大麻的健康问题,并包括了华盛顿州立大学和华盛顿大学大麻研究人员小组最近的一项共识声明。 “吸食含高浓度四氢大麻酚的大麻会增加患上大麻滥用症或大麻成瘾的机会,特别是青少年。使用高效力大麻可造成终生精神健康后果,往往表现在青春期或成年早期。每日吸食大麻,特别是吸食高效力的大麻制品,会增加患精神分裂症等精神疾病的风险,而且与不吸食大麻的人相比,会更早出现症状。“--共识声明摘录 如果通过,该法案将把大麻浓缩物限制在THC的30%以内,并将购买年龄提高到25岁。注册的医用大麻病人可获豁免。 华盛顿的大麻消费者博杰克逊去年曾游说反对一项类似的法案,他说,他正在组织起来,反对今年的尝试。 他告诉Ganjapreneur说:“这将刺激黑市销售,因为超过30%的大麻浓缩物很受欢迎,受到消费者的追捧。”“浓缩物的年龄限制为25岁,这与我们看到的有关烟草和酒精的现行规定不一致,而且似乎是针对大麻消费者的。虽然每个行业都受到监管,但这些监管必须惠及整个社会。这项法案造成了一种任意的限制,伤害了消费者、工业和医疗使用者。“ 结束 作者: 卢卡斯是一名自由撰稿人和医用大麻活动家,住在塔科马。当他不写关于大麻的文章,也不致力于为华盛顿带来更好的大麻医疗系统时,他喜欢做DJ,做适应性运动,在他的塔科马社区做志愿者。他支持全国合法化,并在所有50个州开放医用大麻市场。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文